ERAS
$14.60-0.66 (-4.33%)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal P...
Recent News
Erasca (ERAS) Adds 13%; Soars 310% YTD
Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks Dominating Today’s Market Action. Erasca rallied for a second day on Thursday, jumping 13.04 percent to close at $15.26 apiece on strong investor optimism, backed by earlier optimistic coverage from several analysts. Year-to-date, the company has already seen its stock price soar by 310 percent, making […]
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: ... uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?
In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor vopimetostat in MTAP-deleted pancreatic and RAS-mutant non-small cell lung cancer. The combination seeks to exploit the dependency created by co-occurring MTAP deletions and RAS mutations, aiming for a dual-targeted approach that could more effectively shut down RAS signaling and PRMT5 activity in...
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact
Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.